Should I buy or sell Xenetic Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares. View XBIO analyst ratings or view top-rated stocks .

How have XBIO shares performed in 2024?

Xenetic Biosciences' stock was trading at $3.45 on January 1st, 2024. Since then, XBIO shares have increased by 21.7% and is now trading at $4.20. View the best growth stocks for 2024 here .

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,700 shares, a decline of 22.7% from the March 15th total of 2,200 shares. Based on an average trading volume of 6,100 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's shares are sold short. View Xenetic Biosciences' Short Interest .

When is Xenetic Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our XBIO earnings forecast .

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.10. The company earned $0.67 million during the quarter, compared to the consensus estimate of $0.68 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 36.43% and a negative net margin of 162.84%.

When did Xenetic Biosciences' stock split?

Xenetic Biosciences shares reverse split on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV) , Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Biocept (BIOC) , Trevena (TRVN) , TherapeuticsMD (TXMD) , T2 Biosystems (TTOO) , Vaxart (VXRT) , Aytu BioPharma (AYTU) and Co-Diagnostics (CODX) .

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XBIO

Xenetic Biosciences (XBIO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free XBIO Stock Alerts

$4.20

+0.06 (+1.45%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.98
▼
$4.20
50-Day Range: $3.56
▼
$4.72
52-Week Range: $2.55
▼
$5.97

Volume: 767 shs
Average Volume: 5,951 shs
Market Capitalization: $6.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Xenetic Biosciences alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Xenetic Biosciences Stock (NASDAQ:XBIO)

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

XBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XBIO Stock News Headlines

April 13, 2024 | americanbankingnews.com

Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Drop in Short Interest

April 10, 2024 | investing.com

Xenetic Biosciences Inc (XBIO)

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

March 24, 2024 | finance.yahoo.com

Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 22, 2024 | baystreet.ca

Xenetic Dips on Full-Year Results

March 22, 2024 | msn.com

Xenetic Biosciences reports FY results

January 18, 2024 | msn.com

Xenetic to advance DNase programme with UVA partnership

January 4, 2024 | morningstar.com

Xenetic Biosciences Inc XBIO

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

December 11, 2023 | benzinga.com

Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast

November 30, 2023 | finance.yahoo.com

Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation

November 10, 2023 | benzinga.com

Xenetic Biosciences: Q3 Earnings Insights

November 10, 2023 | washingtonpost.com

MediciNova: Q3 Earnings Snapshot

October 11, 2023 | finance.yahoo.com

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

July 13, 2023 | msn.com

Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?

May 11, 2023 | finance.yahoo.com

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 5, 2023 | morningstar.com

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | Morningstar

May 4, 2023 | finance.yahoo.com

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

May 3, 2023 | finance.yahoo.com

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

April 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation

April 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)

April 11, 2023 | finance.yahoo.com

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

March 16, 2023 | finanznachrichten.de

JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

March 16, 2023 | finance.yahoo.com

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

February 23, 2023 | seekingalpha.com

XBIO Xenetic Biosciences, Inc.

February 21, 2023 | reuters.com

XBIO.PH - | Stock Price & Latest News | Reuters

January 17, 2023 | finance.yahoo.com

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

See More Headlines

Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:XBIO
CUSIP: N/A
CIK: 1534525
Web: www.xeneticbio.com
Phone: 781-778-7720
Fax: N/A
Employees: 4
Year Founded: 2011

Profitability

EPS (Most Recent Fiscal Year): ($2.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,140,000.00
Net Margins: -162.84%
Pretax Margin: -162.79%
Return on Equity: -36.43%
Return on Assets: -33.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.84
Quick Ratio: 11.84

Sales & Book Value

Annual Sales: $2.54 million
Price / Sales: 2.55
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.36 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 1,540,000
Free Float: 1,402,000
Market Cap: $6.47 million
Optionable: Not Optionable
Beta: 2.60

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Jeffrey F. Eisenberg (Age 53)
CEO & Director
Mr. James F. Parslow (Age 54)
CFO, COO & Corp. Sec.
Dr. Curtis A. Lockshin (Age 59)
Chief Scientific Officer

Key Competitors

View All Competitors

XBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Xenetic Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares.
View XBIO analyst ratings or view top-rated stocks.
How have XBIO shares performed in 2024?: Xenetic Biosciences' stock was trading at $3.45 on January 1st, 2024. Since then, XBIO shares have increased by 21.7% and is now trading at $4.20.
View the best growth stocks for 2024 here.
Are investors shorting Xenetic Biosciences?: Xenetic Biosciences saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,700 shares, a decline of 22.7% from the March 15th total of 2,200 shares. Based on an average trading volume of 6,100 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's shares are sold short.
View Xenetic Biosciences' Short Interest.
When is Xenetic Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our XBIO earnings forecast.

How were Xenetic Biosciences' earnings last quarter?: Xenetic Biosciences Inc (NASDAQ:XBIO) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.10. The company earned $0.67 million during the quarter, compared to the consensus estimate of $0.68 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 36.43% and a negative net margin of 162.84%.
When did Xenetic Biosciences' stock split?: Xenetic Biosciences shares reverse split on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Xenetic Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).
How do I buy shares of Xenetic Biosciences?: Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XBIO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial